Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

@article{Tandjung2013ClinicalOF,
  title={Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.},
  author={Kenneth Tandjung and Hanim Sen and Ming Kai Lam and Mounir W. Z. Basalus and Johannes W Louwerenburg and M. G. Stoel and K Gert M van Houwelingen and Frits H. A. F. de Man and Gerard Linssen and Salah A M Sa{\"i}d and Mark B Nienhuis and Marije M. L{\"o}wik and Patrick M. J. Verhorst and Job Am van der Palen and Clemens von Birgelen},
  journal={Journal of the American College of Cardiology},
  year={2013},
  volume={61 24},
  pages={2406-2416}
}
OBJECTIVES The aim of this study was to assess the safety and efficacy of the implantation of Resolute zotarolimus-eluting stents (ZES) (Medtronic Inc., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months. BACKGROUND Only limited long-term follow-up data are available from head-to-head comparisons of second-generation drug-eluting stents. METHODS… CONTINUE READING